Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685404 | 0.82 | MAOA (0.46) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL11657438 | 0.82 | KMT2A (0.41) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL11661100 | 0.82 | KMT2A (0.41) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL11661094 | 0.82 | KMT2A (0.41) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL11657432 | 0.82 | KMT2A (0.41) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL3677388 | 0.82 | TDP1 (0.47) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL1950351 | 0.82 | TDP1 (0.47) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL8353336 | 0.81 | MAOA (0.57) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL22946544 | 0.81 | APLNR (0.44) | MAOAMAOBTDP1MEN1KMT2A | |
| SCHEMBL5147688 | 0.81 | TDP1 (0.43) | MAOAMAOBTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104293-A1 | INHIBITORS OF EIF4A AND USES THEREOF | GUSTAVE ROUSSY TRANSFERT (FR) | 2025-05-22 | — | — | WO | claimed |
| US-20250235462-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM SCIENCES INC (KR) | 2025-07-24 | — | — | US | disclosed |
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| WO-2025104293-A1 | INHIBITORS OF EIF4A AND USES THEREOF | GUSTAVE ROUSSY TRANSFERT (FR) | 2025-05-22 | — | — | WO | disclosed |
| EP-4463458-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| EP-4416150-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | AM Sciences Inc (KR) | 2024-08-21 | — | — | EP | disclosed |
| US-12054494-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2024-08-06 | — | — | US | disclosed |
| CN-118159540-A | Novel capsid assembly inhibitor | 南韩商AM科学股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240166612-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006021882-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050154211-A1 | Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates | KOLB HARTMUTH C (US) | 2005-07-14 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235462-A1 | NOVEL CAPSID ASSEMBLY INHIBITORS | ZC3HAV1, GTF3C3, ZC3HAV1L | MAOA 4438/4885MAOB 4294/4885TDP1 1201/4885 |
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | MAOA 2092/4885MAOB 1952/4885TDP1 4059/4885 |
| US-12054494-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | MAOA 3579/4885MAOB 3972/4885TDP1 3682/4885 |
| US-20050154211-A1 | Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates | OXA1L, ODC1, CYP4B1 | MAOA 1087/4885MAOB 1100/4885TDP1 2232/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | MAOA 454/4885MAOB 258/4885TDP1 4229/4885 |
| US-20240166612-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AGXT, AADAC, AGPAT2 | MAOA 263/4885MAOB 687/4885TDP1 4010/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | MAOA 3616/4885MAOB 3738/4885TDP1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.